|Title:||A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma||Authors:||Yang, Shih Hung
Shao, Yu Yun
Lin, Chia Chi
Kuo, Sung Hsin
Cheng, Ann Lii
Yeh, Kun Huei
|Keywords:||Gemcitabine | Metastasis | Pancreatic ductal adenocarcinoma | Radiotherapy | S-1||Issue Date:||1-Aug-2018||Journal Volume:||38||Journal Issue:||8||Source:||Anticancer Research||Abstract:||
© 2018 International Institute of Anticancer Research. All rights reserved. Background/Aim: Radiotherapy is not routinely used in metastatic pancreatic ductal adenocarcinoma (PDAC). We conducted a phase I study to investigate concurrent chemoradiotherapy (CCRT) followed by chemotherapy. Materials and Methods: S-1 was administered at 50-70 mg/m2/day with radiotherapy in 2.5-3.6 Gy/day for 10-12 fractions. After CCRT, gemcitabine (1,000 mg/m2 on days 1 and 15) and S-1 (60-100 mg/day on days 1-7 and 15-21), were administered in a 4-week cycle. Results: After enrolling 10 patients, the study was terminated due to slow recruitment. Dose-limiting toxicities and maximum tolerated doses were not identified. Most patients experienced mild toxicities, including nausea, vomiting, and anorexia. One patient developed grade 3 infection. One patient achieved partial remission, while the remaining nine patients had stable disease, with a local disease control rate of 100% after CCRT. Conclusion: A short-course CCRT followed by chemotherapy was potentially feasible in patients with metastatic PDAC.
|Appears in Collections:||腫瘤醫學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.